title: [Comparison of tolerance and toxicity of CEF-100 regimen versus CEF-60 regimen as adjuvant therapy for breast cancer].
abstract: OBJECTIVE
  To evaluate tolerance and toxicity of high-dose epirubicin regimen CEF-100 as adjuvant therapy for breast cancer.
  
  
  METHODS
  From March 2005 to October 2006, 98 patients with stage I - III a breast cancer were randomly assigned to receive postoperative chemotherapy with CEF-100 regimen (epirubicin 100 mg/m2, dl per 21 days for 6 cycles, n =48) or CEF-60 regimen (epirubicin 60 mg/m2, dl per 21 days for 6 cycles, n = 50). Blood routine test were done every cycle, liver and kindey function were examined and adverse effects were recorded after every cycle.
  
  
  RESULTS
  No difference of average leucocyte or neutrophil count (P >0.05) was observed in every cycle. Adverse effects of digestive tract and damage of liver function in CEF-100 group were more severe than that in CEF-60 group (P <0.05), but all adverse effects could be relieved by treatment. No severe non-hematological toxicity and cardiac toxicity in both groups were observed (P <0.05). There was no death caused by chemotherapy.
  
  
  CONCLUSIONS
  Our data shows that high dose epirubicin-containing CEF regimen is safe and tolerable for postoperative chemotherapy of breast cancer patient, and the adverse effects could be relieved by marrow support and liver-protection therapy. Further observation and longer follow-up is still needed in order to evaluate the efficacy of this high dose regimen.
authors.affiliation: Department of Breast Cancer, Cancer Hospital, Tianjin Medical University, Tianjin 300060, China.
authors.forename: Rui
authors.initials: R
authors.lastname: Hui
authors.forename: Min
authors.initials: M
authors.lastname: Zhang
authors.forename: Xiao-Meng
authors.initials: XM
authors.lastname: Hao
authors.forename: Jin
authors.initials: J
authors.lastname: Zhang
mesh_terms: D000328:Adult; D000410:Alanine Transaminase / Q000097:blood; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001219:Aspartate Aminotransferases / Q000097:blood; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000601:surgery; D018270:Carcinoma, Ductal, Breast / Q000188:drug therapy* / Q000601:surgery; D018275:Carcinoma, Lobular / Q000188:drug therapy / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D003520:Cyclophosphamide / Q000009:adverse effects / Q000627:therapeutic use; D015251:Epirubicin / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D005472:Fluorouracil / Q000009:adverse effects / Q000627:therapeutic use; D005500:Follow-Up Studies; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008875:Middle Aged; D009503:Neutropenia / Q000139:chemically induced; D014839:Vomiting / Q000139:chemically induced
chemical_list: D015251:Epirubicin; D003520:Cyclophosphamide; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D005472:Fluorouracil